• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评价 YD MolecuTech Real HPV 检测与罗氏 Cobas HPV 检测和 BD Onclarity HPV 检测在 HPV 感染检测中的应用比较。

Evaluation of YD MolecuTech Real HPV Assay in Comparison with Roche Cobas HPV Assay and BD Onclarity HPV Assay for Detection of HPV Infection.

机构信息

Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

Department of Laboratory Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Korea.

出版信息

Ann Clin Lab Sci. 2024 Mar;54(2):239-245.

PMID:38802145
Abstract

OBJECTIVE

Human papillomavirus (HPV) is a double-stranded DNA virus that belongs to the papillomavirus family. High-risk (HR) genotypes of HPV are associated with cervical cancer. The combination of molecular HPV testing and cytology results in an increased detection of high-grade cervical lesions. This study compares the performance of a newly developed MolecuTech Real HPV 16/18/HR assay to that of the cobas HPV assay and Onclarity HPV Assay in Korea.

METHODS

A SurePath liquid-based cytology device (BD diagnostics, NC, USA) was used to prospectively collect cervical swab specimens. Onclarity HPV Assay (Onclarity; BD diagnostics), Cobas 4800 HPV Test (Cobas; Roche, Rotkreuz, Switzerland), and MolecuTech Real HPV 16/18/HR (MolecuTech; YD, Yongin, Korea) were performed to detect HPV genotypes.

RESULTS

Of the 438 cervical specimens, 13.7% showed the HR-HPV genotype. The concordance rates between Onclarity and MolecuTech, cobas and MolecuTech, and Onclarity and Cobas were 94.9% (kappa=0.754), 95.7% (kappa=0.768), and 95.5% (kappa=0.791), respectively. Moreover, no statistically significant differences in HPV genotyping results were observed in the cytology-positive specimens.

CONCLUSIONS

The MolecuTech Real HPV 16/18/HR assay showed good agreement in the detection of HR HPV genotypes, and similar analytical performance for the detection of HR HPV genotypes in samples with abnormal cytological findings.

摘要

目的

人乳头瘤病毒(HPV)是一种双链 DNA 病毒,属于乳头瘤病毒科。高危(HR)型 HPV 与宫颈癌有关。HPV 分子检测与细胞学结果相结合,可提高高级别宫颈病变的检出率。本研究比较了新开发的 MolecuTech Real HPV 16/18/HR 检测与 cobas HPV 检测和 Onclarity HPV 检测在韩国的性能。

方法

使用 SurePath 液基细胞学设备(BD diagnostics,NC,美国)前瞻性收集宫颈拭子标本。进行 Onclarity HPV 检测(Onclarity;BD diagnostics)、Cobas 4800 HPV 检测(Cobas;罗氏,瑞士罗特克)和 MolecuTech Real HPV 16/18/HR(MolecuTech;YD,韩国 Yongin)以检测 HPV 基因型。

结果

在 438 例宫颈标本中,13.7%显示 HR-HPV 基因型。Onclarity 和 MolecuTech、cobas 和 MolecuTech、Onclarity 和 Cobas 的一致性率分别为 94.9%(kappa=0.754)、95.7%(kappa=0.768)和 95.5%(kappa=0.791)。此外,细胞学阳性标本中 HPV 基因分型结果无统计学差异。

结论

MolecuTech Real HPV 16/18/HR 检测在检测 HR HPV 基因型方面具有良好的一致性,并且在检测细胞学异常发现的样本中的 HR HPV 基因型方面具有相似的分析性能。

相似文献

1
Evaluation of YD MolecuTech Real HPV Assay in Comparison with Roche Cobas HPV Assay and BD Onclarity HPV Assay for Detection of HPV Infection.评价 YD MolecuTech Real HPV 检测与罗氏 Cobas HPV 检测和 BD Onclarity HPV 检测在 HPV 感染检测中的应用比较。
Ann Clin Lab Sci. 2024 Mar;54(2):239-245.
2
Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.通过不同类型诊断平台对液基宫颈细胞学样本中的人乳头瘤病毒DNA进行检测和基因分型。
Pathologica. 2018 Dec;110(4):294-301.
3
Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.BD Onclarity HPV 与 digene HC2 High-Risk HPV DNA 检测和 Roche Cobas 4800 HPV 检测用于检测日本高危型人乳头瘤病毒的比较研究。
Am J Clin Pathol. 2019 Feb 4;151(3):263-269. doi: 10.1093/ajcp/aqy124.
4
Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.Onclarity HPV 检测和 Cobas HPV 检测在中国女性宫颈癌前病变和宫颈癌检测中的临床性能。
Gynecol Oncol. 2020 Apr;157(1):202-208. doi: 10.1016/j.ygyno.2020.01.011. Epub 2020 Jan 18.
5
Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens.使用经裁决的 BD SurePath 液基细胞学标本队列评估 BD Onclarity HPV 检测的临床性能。
Am J Clin Pathol. 2014 Jul;142(1):43-50. doi: 10.1309/AJCP53KMHNRDICBL.
6
Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.一种提供扩展型 HPV 分型的人乳头瘤病毒(HPV)DNA 宫颈筛查试验的验证。
J Clin Microbiol. 2018 Apr 25;56(5). doi: 10.1128/JCM.01910-17. Print 2018 May.
7
Concordance between the BD Onclarity and Roche cobas assays for detection of HPV DNA in a Chinese population.在中国人群中,BD Onclarity 与罗氏 cobas 检测 HPV DNA 的一致性。
J Med Virol. 2022 Dec;94(12):6037-6046. doi: 10.1002/jmv.28072. Epub 2022 Sep 5.
8
Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.BD Onclarity HPV 检测在丹麦宫颈筛查项目中使用 SurePath 筛查样本的临床和分析性能,采用 VALGENT 框架。
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01518-19.
9
Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.Onclarity 对亚洲宫颈癌筛查人群中 HPV 基因分型的扩展进行机器学习解释。
J Clin Microbiol. 2019 Nov 22;57(12). doi: 10.1128/JCM.00997-19. Print 2019 Dec.
10
Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.罗氏 Cobas HPV、RFMP HPV PapilloTyper 和杂交捕获 2 检测试剂盒用于检测高危型人乳头瘤病毒的临床性能比较。
J Med Virol. 2015 Sep;87(9):1587-93. doi: 10.1002/jmv.24206. Epub 2015 Apr 24.